Antibiotic Policies and Utilization in Oregon Hospice Programs

Rachel L. Novak, Brie N. Noble, Erik Fromme, Michael O. Tice, Jessina C. McGregor, Jon P. Furuno

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Antibiotics are frequently used in hospice care, despite limited data on safety and effectiveness in this patient population. We surveyed Oregon hospice programs on antibiotic policies and prescribing practices. Among 39 responding hospice programs, the median reported proportion of current census using antibiotics was 10% (interquartile range = 3.5%-20.0%). Approximately 31% of responding hospice programs had policies for antibiotic initiation, 17% of hospice programs had policies for antibiotic discontinuation, and 95% of hospice programs had policies for managing drug interactions. Diarrhea, nausea/vomiting, and yeast infections were the most frequently reported antibiotic-associated adverse events, occurring “sometimes” or “often” among 62%, 47%, and 62% of respondents, respectively. In conclusion, less than a third of participating hospice programs reported having a policy for antibiotic initiation and even less frequently a policy for discontinuation. More data are needed on the risks and benefits of antibiotic use in hospice care to inform these policies and optimize outcomes in this vulnerable patient population.

    Original languageEnglish (US)
    Pages (from-to)777-781
    Number of pages5
    JournalAmerican Journal of Hospice and Palliative Medicine
    Volume33
    Issue number8
    DOIs
    StatePublished - Sep 1 2016

    Fingerprint

    Hospice Care
    Anti-Bacterial Agents
    Vulnerable Populations
    Censuses
    Drug Interactions
    Nausea
    Vomiting
    Diarrhea
    Yeasts
    Safety

    Keywords

    • adverse events
    • antibiotics
    • hospice
    • infection
    • medications
    • policies
    • survey

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Novak, R. L., Noble, B. N., Fromme, E., Tice, M. O., McGregor, J. C., & Furuno, J. P. (2016). Antibiotic Policies and Utilization in Oregon Hospice Programs. American Journal of Hospice and Palliative Medicine, 33(8), 777-781. https://doi.org/10.1177/1049909115599951

    Antibiotic Policies and Utilization in Oregon Hospice Programs. / Novak, Rachel L.; Noble, Brie N.; Fromme, Erik; Tice, Michael O.; McGregor, Jessina C.; Furuno, Jon P.

    In: American Journal of Hospice and Palliative Medicine, Vol. 33, No. 8, 01.09.2016, p. 777-781.

    Research output: Contribution to journalArticle

    Novak, RL, Noble, BN, Fromme, E, Tice, MO, McGregor, JC & Furuno, JP 2016, 'Antibiotic Policies and Utilization in Oregon Hospice Programs', American Journal of Hospice and Palliative Medicine, vol. 33, no. 8, pp. 777-781. https://doi.org/10.1177/1049909115599951
    Novak, Rachel L. ; Noble, Brie N. ; Fromme, Erik ; Tice, Michael O. ; McGregor, Jessina C. ; Furuno, Jon P. / Antibiotic Policies and Utilization in Oregon Hospice Programs. In: American Journal of Hospice and Palliative Medicine. 2016 ; Vol. 33, No. 8. pp. 777-781.
    @article{38084538cf354f8488720b2478ea4c3e,
    title = "Antibiotic Policies and Utilization in Oregon Hospice Programs",
    abstract = "Antibiotics are frequently used in hospice care, despite limited data on safety and effectiveness in this patient population. We surveyed Oregon hospice programs on antibiotic policies and prescribing practices. Among 39 responding hospice programs, the median reported proportion of current census using antibiotics was 10{\%} (interquartile range = 3.5{\%}-20.0{\%}). Approximately 31{\%} of responding hospice programs had policies for antibiotic initiation, 17{\%} of hospice programs had policies for antibiotic discontinuation, and 95{\%} of hospice programs had policies for managing drug interactions. Diarrhea, nausea/vomiting, and yeast infections were the most frequently reported antibiotic-associated adverse events, occurring “sometimes” or “often” among 62{\%}, 47{\%}, and 62{\%} of respondents, respectively. In conclusion, less than a third of participating hospice programs reported having a policy for antibiotic initiation and even less frequently a policy for discontinuation. More data are needed on the risks and benefits of antibiotic use in hospice care to inform these policies and optimize outcomes in this vulnerable patient population.",
    keywords = "adverse events, antibiotics, hospice, infection, medications, policies, survey",
    author = "Novak, {Rachel L.} and Noble, {Brie N.} and Erik Fromme and Tice, {Michael O.} and McGregor, {Jessina C.} and Furuno, {Jon P.}",
    year = "2016",
    month = "9",
    day = "1",
    doi = "10.1177/1049909115599951",
    language = "English (US)",
    volume = "33",
    pages = "777--781",
    journal = "American Journal of Hospice and Palliative Medicine",
    issn = "1049-9091",
    publisher = "SAGE Publications Inc.",
    number = "8",

    }

    TY - JOUR

    T1 - Antibiotic Policies and Utilization in Oregon Hospice Programs

    AU - Novak, Rachel L.

    AU - Noble, Brie N.

    AU - Fromme, Erik

    AU - Tice, Michael O.

    AU - McGregor, Jessina C.

    AU - Furuno, Jon P.

    PY - 2016/9/1

    Y1 - 2016/9/1

    N2 - Antibiotics are frequently used in hospice care, despite limited data on safety and effectiveness in this patient population. We surveyed Oregon hospice programs on antibiotic policies and prescribing practices. Among 39 responding hospice programs, the median reported proportion of current census using antibiotics was 10% (interquartile range = 3.5%-20.0%). Approximately 31% of responding hospice programs had policies for antibiotic initiation, 17% of hospice programs had policies for antibiotic discontinuation, and 95% of hospice programs had policies for managing drug interactions. Diarrhea, nausea/vomiting, and yeast infections were the most frequently reported antibiotic-associated adverse events, occurring “sometimes” or “often” among 62%, 47%, and 62% of respondents, respectively. In conclusion, less than a third of participating hospice programs reported having a policy for antibiotic initiation and even less frequently a policy for discontinuation. More data are needed on the risks and benefits of antibiotic use in hospice care to inform these policies and optimize outcomes in this vulnerable patient population.

    AB - Antibiotics are frequently used in hospice care, despite limited data on safety and effectiveness in this patient population. We surveyed Oregon hospice programs on antibiotic policies and prescribing practices. Among 39 responding hospice programs, the median reported proportion of current census using antibiotics was 10% (interquartile range = 3.5%-20.0%). Approximately 31% of responding hospice programs had policies for antibiotic initiation, 17% of hospice programs had policies for antibiotic discontinuation, and 95% of hospice programs had policies for managing drug interactions. Diarrhea, nausea/vomiting, and yeast infections were the most frequently reported antibiotic-associated adverse events, occurring “sometimes” or “often” among 62%, 47%, and 62% of respondents, respectively. In conclusion, less than a third of participating hospice programs reported having a policy for antibiotic initiation and even less frequently a policy for discontinuation. More data are needed on the risks and benefits of antibiotic use in hospice care to inform these policies and optimize outcomes in this vulnerable patient population.

    KW - adverse events

    KW - antibiotics

    KW - hospice

    KW - infection

    KW - medications

    KW - policies

    KW - survey

    UR - http://www.scopus.com/inward/record.url?scp=84981250830&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84981250830&partnerID=8YFLogxK

    U2 - 10.1177/1049909115599951

    DO - 10.1177/1049909115599951

    M3 - Article

    C2 - 26268730

    AN - SCOPUS:84981250830

    VL - 33

    SP - 777

    EP - 781

    JO - American Journal of Hospice and Palliative Medicine

    JF - American Journal of Hospice and Palliative Medicine

    SN - 1049-9091

    IS - 8

    ER -